Patents by Inventor Helen Morrison

Helen Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEM
    Publication number: 20230053881
    Abstract: A polypeptide is provided that includes an EGF-like domain of a neuregulin protein. A nucleic acid encoding for the polypeptide is also provided. A gene therapy vector inclusive of the nucleic acid and genetically modified cells expressing said polypeptide are also provided. The medical use of the polypeptide, the nucleic acid, the gene therapy vector or the cell for the treatment of tumours of the nervous system are also provided. In particular the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours are provided.
    Type: Application
    Filed: August 1, 2022
    Publication date: February 23, 2023
    Applicant: LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG - FRITZ-LIPMANN-INSTITUT E.V. (FLI)
    Inventors: Alexander Schulz, Helen Morrison
  • Neuregulin for the treatment of tumors of the nervous system
    Patent number: 11426447
    Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 30, 2022
    Assignee: LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG—FRITZ-LIPMANN-INSTITUT E.V. (FLI)
    Inventors: Alexander Schulz, Helen Morrison
  • NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEM
    Publication number: 20210213100
    Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
    Type: Application
    Filed: April 19, 2017
    Publication date: July 15, 2021
    Inventors: Alexander SCHULZ, Helen MORRISON
  • Method for identifying compounds for modulating the activity of a tumor suppressor protein
    Publication number: 20040072171
    Abstract: The present invention relates to a method for identifying compounds which modify the activity of the intracellular tumor suppressor gene nf2, where the activity of the protein NF2, which is encoded by the gene nf2, is modified by an extracellular interaction of the compounds with the cell surface protein CD44.
    Type: Application
    Filed: May 13, 2003
    Publication date: April 15, 2004
    Inventors: Helen Morrison, Helmut Ponta, Peter Herrlich